GONZALEZ DE REQUENA, Daniel
 Distribuzione geografica
Continente #
NA - Nord America 1.258
EU - Europa 646
AS - Asia 263
SA - Sud America 13
Totale 2.180
Nazione #
US - Stati Uniti d'America 1.252
DK - Danimarca 287
CN - Cina 120
SG - Singapore 94
SE - Svezia 57
IE - Irlanda 50
IT - Italia 50
FR - Francia 40
AT - Austria 37
FI - Finlandia 37
KR - Corea 27
DE - Germania 26
GB - Regno Unito 18
UA - Ucraina 14
BR - Brasile 11
NL - Olanda 8
PL - Polonia 8
BE - Belgio 5
CA - Canada 5
IN - India 5
VN - Vietnam 5
ES - Italia 4
HK - Hong Kong 3
TH - Thailandia 3
CZ - Repubblica Ceca 2
ID - Indonesia 2
PH - Filippine 2
AR - Argentina 1
BG - Bulgaria 1
CO - Colombia 1
IM - Isola di Man 1
JP - Giappone 1
MX - Messico 1
SI - Slovenia 1
TW - Taiwan 1
Totale 2.180
Città #
Ann Arbor 558
Chandler 120
Santa Clara 91
Beijing 86
Singapore 62
Dublin 50
Dearborn 36
Villeurbanne 35
Vienna 34
Nyköping 29
Princeton 27
Ashburn 26
Houston 23
Medford 22
Torino 20
New York 18
Wilmington 17
Jacksonville 14
Columbus 12
Guangzhou 11
Redwood City 8
Warsaw 8
Boardman 7
Fremont 7
Milan 7
Nuremberg 7
Seattle 6
Brussels 5
Fairfield 5
Munich 5
Hangzhou 4
Toronto 4
Boston 3
Helsinki 3
Hong Kong 3
Jinan 3
London 3
Woodbridge 3
Amsterdam 2
Bangkok 2
Des Moines 2
Falls Church 2
Frankfurt am Main 2
Jakarta 2
Los Angeles 2
Madrid 2
Nanjing 2
Pune 2
Redmond 2
Rome 2
Uberlândia 2
Verona 2
Wuhan 2
Barra Mansa 1
Bauru 1
Bogotá 1
Brno 1
Buenos Aires 1
Buting 1
Chapecó 1
Chicago 1
Chongqing 1
Costa Mesa 1
Curado 1
Dong Ket 1
Douglas 1
Easton 1
Edinburgh 1
Falkenstein 1
Florence 1
Fuzhou 1
Granollers 1
Hamburg 1
Handan 1
Januária 1
Kunming 1
Linhares 1
Ljubljana 1
Manchester 1
Mauá 1
Mexico City 1
Miami 1
Mountain View 1
Nanchang 1
Ottawa 1
Pomorie 1
Prague 1
San Diego 1
San Jose 1
Santana do Livramento 1
Sao Paulo 1
Shanghai 1
Shaoxing 1
Turin 1
Umeda 1
Vancouver 1
Villanueva De Los Infantes 1
Xian 1
Totale 1.457
Nome #
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 186
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 179
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 168
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 168
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 162
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 158
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 158
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 156
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 155
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 150
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 146
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. 95
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 90
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) 82
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon 77
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens 76
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 75
Totale 2.281
Categoria #
all - tutte 5.855
article - articoli 0
book - libri 0
conference - conferenze 4.210
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.065


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020205 0 0 0 0 0 0 0 0 3 43 71 88
2020/2021197 71 1 0 13 9 7 8 3 11 10 6 58
2021/2022591 64 55 57 65 49 49 64 51 40 7 52 38
2022/2023339 30 12 10 47 28 95 16 22 38 3 21 17
2023/2024117 13 24 6 7 9 27 1 7 0 4 3 16
2024/2025258 1 7 12 23 132 40 1 17 25 0 0 0
Totale 2.281